ARA-290 Peptide: Molecular Structure, Mechanism of Action, and Scientific Research

• What it is: an 11-residue synthetic peptide (pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser) derived from the helix B region of erythropoietin.
• Identity: CAS 1208243-50-8; molecular formula C₅₁H₈₄N₁₆O₂₁; molecular weight about 1257.3 g/mol.
• Research focus: the proposed innate repair receptor (EPOR/CD131), studied apart from the classical EPO receptor behind red-blood-cell production.
• Evidence: small, early-stage clinical studies plus preclinical work. Long-term outcomes have not been established.
• Status: investigational. No regulator has cleared it for any use.

ARA-290 is a synthetic peptide built from structural features of erythropoietin, a naturally occurring glycoprotein hormone best known for its role in red blood cell production. Researchers designed ARA-290 to study tissue-protective signaling pathways separately from that erythropoietic response.

That separation has made it a research tool in experimental studies of inflammatory signaling, cellular stress responses, peripheral nerve biology and tissue repair. The original design work was reported by Brines and colleagues in 2008.

ARA-290 reproduces selected spatial features of the helix B surface of erythropoietin in a short, linear chain. Its N-terminal residue is pyroglutamic acid.

Its short chain makes it a useful model for studying how one structural element of a larger protein can engage a cellular signaling system. See the ARA-290 product page for batch specifications and testing documentation.

A central research question is ARA-290’s proposed interaction with the innate repair receptor (IRR). The IRR has been described as a receptor complex of the erythropoietin receptor (EPOR) and the β-common receptor (CD131), proposed to take part in cellular responses to cell damage, inflammation and tissue stress.

How does ARA-290 differ from erythropoietin?

Erythropoietin is associated with two distinct areas of activity:

1. Erythropoiesis: red blood cell production, signaled through the classical EPO receptor homodimer.
2. Tissue-protective signaling: proposed signaling through the EPOR/CD131 complex in response to cellular stress.

ARA-290 was developed to study the second pathway while keeping activation of the first to a minimum. In a mouse sciatic-nerve damage model reviewed by Dahan and colleagues (2016), ARA-290’s effects were absent in animals lacking the β-common receptor, which supports the proposed role of CD131. The precise receptor interactions and downstream mechanisms are still being investigated.

Peripheral nerve biology is the most studied area for ARA-290. The studies below are summarized as research context only. They are small, early-stage studies and do not establish safety or effectiveness.

Small fiber nerve loss associated with sarcoidosis

A blinded, placebo-controlled study by Dahan and colleagues (Molecular Medicine, 2013) examined ARA-290 over 28 days in people with sarcoidosis-associated small nerve fiber loss. The investigators reported changes in neuropathic symptom scores, an increase in corneal nerve fiber density, changes in skin temperature sensitivity and a longer 6-minute walk distance. A 2016 correction revised the study’s corneal nerve fiber calculations, so the published corneal figures should be read together with that correction.

Type 2 diabetes and painful neuropathy

A phase 2, placebo-controlled study by Brines and colleagues (Molecular Medicine, 2015) followed participants with type 2 diabetes and painful neuropathy for 28 days of study treatment and a further month of follow-up. The authors reported improvements in HbA1c and lipid measures and in neuropathic symptom questionnaire (PainDetect) scores in the ARA-290 group compared with placebo, and called for further clinical evaluation.

These observations raised interest in how erythropoietin-derived peptides relate to metabolic regulation and peripheral nerve biology. They are not proof that ARA-290 is effective for any condition.

Inflammatory responses involve complex interactions among immune cells, signaling proteins, receptors and cellular repair mechanisms. Preclinical work has asked whether erythropoietin-derived peptides shift selected inflammation and stress pathways. Open questions include:

• How proposed innate repair receptor signaling changes after cell damage.
• Whether receptor-associated signaling alters the expression of inflammatory mediators.
• How experimental tissue models respond to cellular stress.
• Whether downstream signaling differs from classical EPO receptor activity.

These are mechanistic research questions, not established effects. For related background, see our overview of peptides in cell signaling research.

Tissue repair involves overlapping processes: inflammatory regulation, cell survival, extracellular matrix remodeling and restoration of tissue function. ARA-290 draws research attention because of its proposed link to endogenous protective signaling, and preclinical studies have examined erythropoietin-derived peptides in models of tissue damage and inflammatory stress.

Results from isolated cells or animal models can’t be assumed to apply to humans. Independently replicated studies are needed to show which findings hold up.

• Clinical sample sizes have been small.
• Study durations have been short.
• Studies used different endpoints, which makes them hard to compare.
• Independent replication is limited.
• Long-term safety and effectiveness have not been established.
• One key study needed a published correction to its corneal measurements, a reminder to read primary sources and their updates critically.

ARA-290 remains investigational, and no regulator has cleared it for any use. The published research is preliminary scientific evidence, not confirmation of an application.

For laboratories working with synthetic peptides, analytical characterization establishes identity, purity and consistency. Several complementary methods apply.

High-performance liquid chromatography (HPLC)

HPLC evaluates purity and chromatographic behavior. A validated method separates the main peptide peak from related impurities, but an HPLC purity figure alone does not establish identity or absolute peptide content.

Mass spectrometry

Mass spectrometry supports identity by measuring molecular mass (about 1256.6 Da monoisotopic for ARA-290) and, depending on the method, structural information. This matters when telling closely related synthetic peptides apart.

Peptide content

Content testing answers a different question from purity: how much of the target peptide is present, rather than its relative share under one method. Both support reproducible research.

Batch documentation

Useful documentation includes the compound and batch number, analytical methods and test dates, chromatographic purity, identity confirmation, peptide content when measured, and method limits and acceptance criteria. See our guide to reading a peptide certificate of analysis.

ARA-290 is an example of structure-guided peptide design based on erythropoietin. Its short sequence and proposed interaction with the innate repair receptor have made it a research subject in peripheral nerve biology, inflammatory signaling and cellular stress. Early clinical studies produced preliminary findings, but questions remain about receptor biology, reproducibility, long-term safety and relevance. Continued research and rigorous analytical characterization are what will clarify them.

1. Brines M, et al. ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes. Molecular Medicine. 2015;20:658–666. PubMed 25387363 · doi:10.2119/molmed.2014.00215
2. Dahan A, et al. ARA 290 Improves Symptoms in Patients with Sarcoidosis-Associated Small Nerve Fiber Loss and Increases Corneal Nerve Fiber Density. Molecular Medicine. 2013;19:334–345. PubMed 24136731 · doi:10.2119/molmed.2013.00122 (see also the 2016 correction)
3. Dahan A, Brines M, Niesters M, Cerami A, van Velzen M. Targeting the Innate Repair Receptor to Treat Neuropathy. Pain Reports. 2016;1(1):e566. PMC5741312 · doi:10.1097/PR9.0000000000000566
4. Brines M, et al. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. PNAS. 2008. doi:10.1073/pnas.0805594105

This article is for scientific and educational purposes. It summarizes published research on an investigational compound and is not guidance for human or veterinary use. NuRev Peptides does not provide use instructions of any kind. References to published research do not mean any NuRev product was evaluated in, or is equivalent to material used in, the cited studies.